Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Prog Neurobiol. 2009 Feb 7;88(1):17–31. doi: 10.1016/j.pneurobio.2009.01.009

Figure 2. Simplified Model of 5-HT1A Receptor-Mediated Therapeutic Effects of AD.

Figure 2

Figure 2

AD are hypothesised to increase serotonergic signaling at the postsynaptic 5-HT1A receptor either by desensitizing the somatodendritic 5-HT1A receptor in the raphe, or by facilitating the activation of G proteins by the postsynaptic 5-HT1A receptor. Normalized signaling at the postsynaptic 5-HT1A receptor reduces cortisol and CRH release, restores endocrine function, and improves mood.